Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Silence Therapeutics. The associated price target remains the same with $75.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Silence Therapeutics’ strong potential for growth. The company is advancing multiple promising programs, including divesiran for polycythemia vera (PV) and zerlasiran for lipoprotein(a) [Lp(a)], both of which have shown significant progress in clinical trials. The updated Phase 1 data for divesiran, presented at the European Hematology Association, demonstrated effective hematocrit control and improved patient outcomes, positioning it as a potential first-in-class treatment.
Moreover, Silence Therapeutics is strategically prioritizing its resources by pausing less critical projects to focus on high-impact initiatives like PV and extra-hepatic delivery. The company’s collaboration with AstraZeneca and a strong cash position, with sufficient funds to sustain operations into 2028, further reinforce its financial stability and growth prospects. These factors, combined with upcoming clinical and business development milestones, support the analyst’s confidence in the stock’s upside potential, leading to the reiterated Buy rating and a price target of $75.
Trucchio covers the Healthcare sector, focusing on stocks such as GH Research, Arrowhead Pharmaceuticals, and Oncolytics Biotech. According to TipRanks, Trucchio has an average return of 13.6% and a 47.23% success rate on recommended stocks.